Philomena Lip

Philomena Lip is a venture capital professional and analyst at Advent Life Sciences based in the United Kingdom. Operating within the transatlantic venture capital firm, she evaluates early and mid-stage investments across the biotechnology, medical technology, and pharmaceutical sectors. Her investment evaluation work involves assessing companies focused on new drug discovery, enabling technologies, and vaccines, with direct exposure to prominent portfolio companies such as AviadoBio and Amphista Therapeutics. Expanding her corporate governance responsibilities within the biotechnology sector, she was officially appointed as a board director of Cenentry Biosciences Limited on June 20, 2024. Prior to this board appointment, she built her foundational venture capital experience by analyzing complex medical device and drug development markets. Lip currently focuses on identifying and supporting innovative therapeutic modalities, including gene therapy for neurodegenerative disorders and targeted protein degradation for cancer therapies.